No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM

Journal of Infection

Volumn 69, Issue 4, 2014, Pages 375-386

  Mooij, Sofie H ^a,c   Landén, Olivia ^a   van der Klis, Fiona R M ^b   van der Sande, Marianne A B ^b,e   de Melker, Hester E ^b   Coutinho, Roel A ^b,e   van Eeden, Arne ^d,g   van Rooijen, Martijn S ^a   Meijer, Chris J L M ^f   Schim van der Loeff, Maarten F ^a,c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Jan Van Goyen Medical Center   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g DC Klinieken   (Netherlands)

Author keywords

Anal; Antibodies; HPV; Immunology; Penile; Protection

Indexed keywords

HUMAN PAPILLOMAVIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ANAL INFECTION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FOLLOW UP; GASTROINTESTINAL INFECTION; GENOTYPE; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS NEGATIVE PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNOASSAY; INCIDENCE; INFECTION RISK; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT INFECTION; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MULTIPLEX IMMUNOASSAY; PAPILLOMAVIRUS INFECTION; PATIENT; PENILE INFECTION; SENSITIVITY ANALYSIS; SEROPREVALENCE; SEXUAL BEHAVIOR; ANUS DISEASES; BLOOD; HIV INFECTIONS; IMMUNOLOGY; MALE HOMOSEXUALITY; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE DISEASES; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; ANUS DISEASES; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE DISEASES;

EID: 84908507782     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.06.003     Document Type: Article

References (33)

1. Giuliano A.R., Tortolero-Luna G., Ferrer E., Burchell A.N., de Sanjosé S., Kjaer S.K., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(Suppl. 10):K17-K28.
2. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
3. Stanley M. HPV -; immune response to infection and vaccination. Infect Agent Cancer 2010, 5:19.
4. Gravitt P.E. The known unknowns of HPV natural history. J Clin Invest 2011, 121(12):4593-4599.
5. Mollers M., Vossen J.M., Scherpenisse M., van der Klis F.R., Meijer C.J., de Melker H.E. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013, 85(8):1379-1385.
6. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765.
7. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24(27-28):5571-5583.
8. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
9. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364(5):401-411.
10. Machalek D.A., Poynten M., Jin F., Fairley C.K., Farnsworth A., Garland S.M., et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012, 13(5):487-500.
11. Piketty C., Selinger-Leneman H., Bouvier A.M., Belot A., Mary-Krause M., Duvivier C., et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 2012, 30:4360-4366.
12. Jansen I.A., Geskus R.B., Davidovich U., Jurriaans S., Coutinho R.A., Prins M., et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS 2011, 25(4):493-501.
13. Heijman R.L., Stolte I.G., Thiesbrummel H.F., van Leent E., Coutinho R.A., Fennema J.S., et al. Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic. Sex Transm Infect 2009, 85(4):249-255.
14. van Aar F., Mooij S.H., van der Sande M.A., Speksnijder A.G., Stolte I.G., Meijer C.J., et al. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS 2013, 27:2821-2831.
15. Mooij S.H., Boot H.J., Speksnijder A.G., Stolte I.G., Meijer C.J., Snijders P.J., et al. Oral human papillomavirus infection in HIV-negative and HIV-infected men who have sex with men: the HIV & HPV in MSM (H2M) study. AIDS 2013, 27:2117-2128.
16. Scherpenisse M., Mollers M., Schepp R.M., Boot H.J., de Melker H.E., Meijer C.J., et al. Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 2012, 30(47):6686-6693.
17. Scherpenisse M., Schepp R.M., Mollers M., Meijer C.J., Berbers G.A., van der Klis F.R. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 2013, 8(9):e74797.
18. Frey A., Di C.J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221(1-2):35-41.
19. Van Doorn L.J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44(9):3292-3298.
20. Xue X., Gange S.J., Zhong Y., Burk R.D., Minkoff H., Massad L.S., et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19(1):159-169.
21. Mooij S.H., van der Klis F.R., van der Sande M.A., Schepp R.M., Speksnijder A.G., Bogaards J.A., et al. Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2M Study. Cancer Epidemiol Biomarkers Prev 2013, 22(10):1698-1708.
22. Lin S.W., Ghosh A., Porras C., Markt S.C., Rodriguez A.C., Schiffman M., et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 2013, 8(1):e53067.
23. Malik Z.A., Hailpern S.M., Burk R.D. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009, 22(6):445-449.
24. Safaeian M., Porras C., Schiffman M., Rodriguez A.C., Wacholder S., Gonzalez P., et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102(21):1653-1662.
25. Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002, 186(6):737-742.
26. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004, 13(2):324-327.
27. Viscidi R.P., Snyder B., Cu-Uvin S., Hogan J.W., Clayman B., Klein R.S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005, 14(1):283-288.
28. Lu B., Hagensee M.E., Lee J.H., Wu Y., Stockwell H.G., Nielson C.M., et al. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev 2010, 19(2):511-516.
29. Lu B., Viscidi R.P., Wu Y., Lee J.H., Nyitray A.G., Villa L.L., et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012, 72(3):676-685.
30. Robbins H.A., Li Y., Porras C., Pawlita M., Ghosh A., Rodriguez A.C., et al. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis 2014, 14:120.
31. Lu B., Viscidi R.P., Wu Y., Nyitray A.G., Villa L.L., Lazcano-Ponce E., et al. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev 2012, 21(9):1542-1546.
32. Heiligenberg M., Alberts C.J., Waterboer T., Speksnijder A.G., de Vries H.J., Pawlita M., et al. Route of sexual exposure is independently associated with seropositivity to HPV-16 and HPV-18 among clients of an STI clinic in the Netherlands. J Infect Dis 2013, 208(7):1081-1085.
33. Scherpenisse M., Mollers M., Schepp R.M., Meijer C.J., de Melker H.E., Berbers G.A., et al. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother 2012, 9(2):314-321.